Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25


A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability.

Sirois I, Aguilar-Mahecha A, Lafleur J, Fowler E, Vu V, Scriver M, Buchanan M, Chabot C, Ramanathan A, Balachandran B, Légaré S, Przybytkowski E, Lan C, Krzemien U, Cavallone L, Aleynikova O, Ferrario C, Guilbert MC, Benlimame N, Saad A, Alaoui-Jamali M, Saragovi HU, Josephy S, O'Flanagan C, Hursting SD, Richard VR, Zahedi RP, Borchers CH, Bareke E, Nabavi S, Tonellato P, Roy JA, Robidoux A, Marcus EA, Mihalcioiu C, Majewski J, Basik M.

Mol Cancer Res. 2019 Dec;17(12):2492-2507. doi: 10.1158/1541-7786.MCR-19-0264. Epub 2019 Sep 19.


Metastatic Breast Carcinoma-Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression.

Gui Y, Aguilar-Mahecha A, Krzemien U, Hosein A, Buchanan M, Lafleur J, Pollak M, Ferrario C, Basik M.

Clin Cancer Res. 2019 Dec 1;25(23):7229-7242. doi: 10.1158/1078-0432.CCR-19-1268. Epub 2019 Sep 12.


Precision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case Report.

Aguilar-Mahecha A, Joseph S, Cavallone L, Buchanan M, Krzemien U, Batist G, Basik M.

Front Oncol. 2019 Aug 6;9:698. doi: 10.3389/fonc.2019.00698. eCollection 2019.


Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells.

Ghashghaei M, Niazi TM, Aguilar-Mahecha A, Klein KO, Greenwood CMT, Basik M, Muanza TM.

Sci Rep. 2019 Jun 20;9(1):8838. doi: 10.1038/s41598-019-44991-w.


An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy.

Darini C, Ghaddar N, Chabot C, Assaker G, Sabri S, Wang S, Krishnamoorthy J, Buchanan M, Aguilar-Mahecha A, Abdulkarim B, Deschenes J, Torres J, Ursini-Siegel J, Basik M, Koromilas AE.

Nat Commun. 2019 May 13;10(1):2139. doi: 10.1038/s41467-019-10138-8.


A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR.

Cavallone L, Aldamry M, Lafleur J, Lan C, Gonzalez Ginestet P, Alirezaie N, Ferrario C, Aguilar-Mahecha A, Basik M.

Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):909-916. doi: 10.1158/1055-9965.EPI-18-0586. Epub 2019 Mar 1.


Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors.

Popp R, Li H, LeBlanc A, Mohammed Y, Aguilar-Mahecha A, Chambers AG, Lan C, Poetz O, Basik M, Batist G, Borchers CH.

Anal Chem. 2017 Oct 3;89(19):10592-10600. doi: 10.1021/acs.analchem.7b02934. Epub 2017 Sep 20.


The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience.

Aguilar-Mahecha A, Lafleur J, Pelmus M, Seguin C, Lan C, Discepola F, Kovacina B, Christodoulopoulos R, Salvucci O, Mihalcioiu C, Roy JA, Robidoux A, Marcus EA, Batist G, Basik M.

Mod Pathol. 2017 Nov;30(11):1567-1576. doi: 10.1038/modpathol.2017.82. Epub 2017 Jul 28.


PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer.

Dupuy F, Tabariès S, Andrzejewski S, Dong Z, Blagih J, Annis MG, Omeroglu A, Gao D, Leung S, Amir E, Clemons M, Aguilar-Mahecha A, Basik M, Vincent EE, St-Pierre J, Jones RG, Siegel PM.

Cell Metab. 2015 Oct 6;22(4):577-89. doi: 10.1016/j.cmet.2015.08.007. Epub 2015 Sep 10.


Glycoproteomic comparison of clinical triple-negative and luminal breast tumors.

Hill JJ, Tremblay TL, Fauteux F, Li J, Wang E, Aguilar-Mahecha A, Basik M, O'Connor-McCourt M.

J Proteome Res. 2015 Mar 6;14(3):1376-88. doi: 10.1021/pr500987r. Epub 2015 Feb 16.


Testing devices or experimental systems? Cancer clinical trials take the genomic turn.

Nelson NC, Keating P, Cambrosio A, Aguilar-Mahecha A, Basik M.

Soc Sci Med. 2014 Jun;111:74-83. doi: 10.1016/j.socscimed.2014.04.008. Epub 2014 Apr 12.


Biopsies: next-generation biospecimens for tailoring therapy.

Basik M, Aguilar-Mahecha A, Rousseau C, Diaz Z, Tejpar S, Spatz A, Greenwood CM, Batist G.

Nat Rev Clin Oncol. 2013 Aug;10(8):437-50. doi: 10.1038/nrclinonc.2013.101. Epub 2013 Jun 25. Review. Erratum in: Nat Rev Clin Oncol. 2013 Nov;10(11):608.


Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine.

Diaz Z, Aguilar-Mahecha A, Paquet ER, Basik M, Orain M, Camlioglu E, Constantin A, Benlimame N, Bachvarov D, Jannot G, Simard MJ, Chabot B, Gologan A, Klinck R, Gagnon-Kugler T, Lespérance B, Samson B, Kavan P, Alcindor T, Dalfen R, Lan C, Chabot C, Buchanan M, Przybytkowski E, Qureshi S, Rousseau C, Spatz A, Têtu B, Batist G.

Mod Pathol. 2013 Nov;26(11):1413-24. doi: 10.1038/modpathol.2013.81. Epub 2013 Jun 7.


Ultradense array CGH and discovery of micro-copy number alterations and gene fusions in the cancer genome.

Przybytkowski E, Aguilar-Mahecha A, Nabavi S, Tonellato PJ, Basik M.

Methods Mol Biol. 2013;973:15-38. doi: 10.1007/978-1-62703-281-0_2.


The effect of pre-analytical variability on the measurement of MRM-MS-based mid- to high-abundance plasma protein biomarkers and a panel of cytokines.

Aguilar-Mahecha A, Kuzyk MA, Domanski D, Borchers CH, Basik M.

PLoS One. 2012;7(6):e38290. doi: 10.1371/journal.pone.0038290. Epub 2012 Jun 6.


CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model.

Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, Muller WJ, Alsawafi Y, Mourskaia AA, Siegel PM, Salvucci O, Basik M.

Int J Cancer. 2011 Jul 1;129(1):225-32. doi: 10.1002/ijc.25665. Epub 2010 Nov 12.


Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner.

Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E, Yuan S, Young YK, Boivin MN, Forner K, Basik M, Galipeau J.

J Immunol. 2009 May 15;182(10):5994-6002. doi: 10.4049/jimmunol.0803962.


Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker.

Aguilar-Mahecha A, Cantin C, O'Connor-McCourt M, Nantel A, Basik M.

Proteome Sci. 2009 Apr 6;7:15. doi: 10.1186/1477-5956-7-15.


Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers.

Hamel S, Bouchard A, Ferrario C, Hassan S, Aguilar-Mahecha A, Buchanan M, Quenneville L, Miller W, Basik M.

Breast Cancer Res Treat. 2010 Feb;120(1):47-57. doi: 10.1007/s10549-009-0364-7. Epub 2009 Mar 20.


Microarrays as validation strategies in clinical samples: tissue and protein microarrays.

Aguilar-Mahecha A, Hassan S, Ferrario C, Basik M.

OMICS. 2006 Fall;10(3):311-26. Review.


The stress response in gametes and embryos after paternal chemical exposures.

Hales BF, Aguilar-Mahecha A, Robaire B.

Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):514-20. Review.


Effects of acute and chronic cyclophosphamide treatment on meiotic progression and the induction of DNA double-strand breaks in rat spermatocytes.

Aguilar-Mahecha A, Hales BF, Robaire B.

Biol Reprod. 2005 Jun;72(6):1297-304. Epub 2005 Jan 26.


Chronic cyclophosphamide treatment alters the expression of stress response genes in rat male germ cells.

Aguilar-Mahecha A, Hales BF, Robaire B.

Biol Reprod. 2002 Apr;66(4):1024-32.


Expression of stress response genes in germ cells during spermatogenesis.

Aguilar-Mahecha A, Hales BF, Robaire B.

Biol Reprod. 2001 Jul;65(1):119-27.


Supplemental Content

Loading ...
Support Center